These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7012190)

  • 21. High dosage haloperidol in chronic schizophrenia.
    McCreadie RG; MacDonald IM
    Br J Psychiatry; 1977 Sep; 131():310-6. PubMed ID: 334315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implications of the efficacy of thiothixene and a chlorpromazine-imipramine combination for depression in schizophrenia.
    Becker RE
    Am J Psychiatry; 1983 Feb; 140(2):208-11. PubMed ID: 6336916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness.
    Pinder RM; Brogden RN; Speight TM; Avery GS
    Drugs; 1977 Jun; 13(6):401-21. PubMed ID: 324751
    [No Abstract]   [Full Text] [Related]  

  • 24. Does viloxazine really improve sex drive? A double-blind controlled study.
    De Leo D; Magni G
    Br J Psychiatry; 1986 May; 148():597-9. PubMed ID: 3535972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Viloxazine in the treatment of depression in the aged. Double-blind placebo study].
    De Leo D; Ceola A; Magni G; Renesto V; Pacchioni A
    Minerva Psichiatr; 1984; 25(2):127-30. PubMed ID: 6387360
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical profile and serum concentration of viloxazine as compared to amitriptyline.
    Müller-Oerlinghausen B; Rüther E
    Pharmakopsychiatr Neuropsychopharmakol; 1979 Jul; 12(4):321-37. PubMed ID: 386390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of the effect of viloxazine in the sexual sphere. Double-blind study versus placebo].
    De Leo D
    Clin Ter; 1985 Nov; 115(4):253-9. PubMed ID: 4085181
    [No Abstract]   [Full Text] [Related]  

  • 28. [Double blind comparison of the antidepressives viloxazine and imipramine (author's transl)].
    Pöldinger W
    Dtsch Med Wochenschr; 1982 Apr; 107(17):661-5. PubMed ID: 7075479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Synopsis of psychopathological, electroencephalographical, and pharmacokinetic variables during antidepressive treatment with viloxazine (author's transl)].
    Busch H; Bente D; Müller-Oerlinghausen B; Renfordt E
    Arzneimittelforschung; 1978; 28(8):1288-90. PubMed ID: 380579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicentre study with viloxazine (Vivalan) in depressed patients.
    Kabes J; Dostal T; Náhunek K; Svestka J; Molcan J; Caplová T; Hynek K; Faltus F; Holland RP
    Int Pharmacopsychiatry; 1980; 15(4):228-39. PubMed ID: 7021448
    [No Abstract]   [Full Text] [Related]  

  • 31. A comparative study of viloxazine and imipramine in the treatment of depressive states.
    Elwan O
    J Int Med Res; 1980; 8(1):7-17. PubMed ID: 7358207
    [No Abstract]   [Full Text] [Related]  

  • 32. Viloxazine HCl in the treatment of endogenous depression: a standard (imipramine) controlled clinical study.
    McEvoy JP; Libiger J; Wilson WH; Ban TA; Berney S; Guy W
    J Clin Psychiatry; 1982 Mar; 43(3):111-2. PubMed ID: 7037758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A placebo controlled trial of viloxazine with and without tranquillizers in depressive illness.
    Magnus RV
    J Int Med Res; 1975; 3(3):207-13. PubMed ID: 162677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Doubleblind study with the novel antidepressant viloxazine versus imipramine in 50 in-patients (author's transl)].
    Floru L; Czarny G; Tegeler J
    Arzneimittelforschung; 1976; 26(6):1170-1. PubMed ID: 786314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial.
    Kramer MS; Vogel WH; DiJohnson C; Dewey DA; Sheves P; Cavicchia S; Little P; Schmidt R; Kimes I
    Arch Gen Psychiatry; 1989 Oct; 46(10):922-8. PubMed ID: 2679483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Viloxazine in the treatment of depressive states.
    Rydzyński Z; Gruszczyński W
    Act Nerv Super (Praha); 1979 Oct; 21(3):146-7. PubMed ID: 556241
    [No Abstract]   [Full Text] [Related]  

  • 37. Unwanted symptoms in depressed patients treated with viloxazine: an algorithm for identification of illness-related symptoms.
    Maistrello I; Grassi G; Bertolino A; Valerio P; Pistollato G; Soverini S
    Eur J Clin Pharmacol; 1983; 24(2):277-81. PubMed ID: 6840180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A clinical and pharmacological study of the antidepressant activity of viloxazine in adult and elderly patients.
    Tosca P; Zerbi F; Romani A; Molini G; Cairoli S; Montagna M; Gabba A; Groppi A
    Int J Clin Pharmacol Ther Toxicol; 1985 May; 23(5):270-3. PubMed ID: 4008117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Viloxazine: a review of the literature.
    Ban TA; McEvoy JP; Wilson WH
    Int Pharmacopsychiatry; 1980; 15(2):118-23. PubMed ID: 7002831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of secondary depression in schizophrenia. A double-blind, placebo-controlled trial of amitriptyline added to perphenazine.
    Prusoff BA; Williams DH; Weissman MM; Astrachan BM
    Arch Gen Psychiatry; 1979 May; 36(5):569-75. PubMed ID: 373665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.